Biodistribution data from 100 patients i.v. injected with 111In-DTPA-D-Phe1-octreotide

Acta Oncologica

Volumn 43, Issue 5, 2004, Pages 436-442

  Forssell Aronsson, Eva ^a   Bernhardt, Peter ^a   Nilsson, Ola ^a   Tisell, Lars Erik ^a   Wängberg, Bo ^a   Ahlman, Håkan ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

PENTETREOTIDE IN 111;

ADULT; AGED; ARTICLE; BIOPSY; BREAST CARCINOMA; CARCINOID; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; DOSIMETRY; DRUG DISTRIBUTION; FEMALE; HUMAN; HUMAN TISSUE; ISOTOPE LABELING; KIDNEY; KIDNEY CARCINOMA; LIVER; MAJOR CLINICAL STUDY; MALE; PANCREAS TUMOR; PRIORITY JOURNAL; SPLEEN; THYROID MEDULLARY CARCINOMA; THYROID TUMOR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; INDIUM RADIOISOTOPES; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASMS; OCTREOTIDE; PENTETIC ACID; TISSUE DISTRIBUTION;

EID: 3843139508     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/02841860410030670     Document Type: Article

References (30)

1. Fjälling M, Andersson P, Forssell-Aronsson E, et al. Systemic radionuclide therapy using indium-111-DTPA-D-Phe1-octreotide in midgut carcinoid syndrome. J Nucl Med 1996; 37: 1519-21.
2. 111In-DTPA-D-Phe1]-octreotide. A case history. Ann N Y Acad Sci 1994; 733: 496-506.
3. de Jong M, Breeman WA, Bernard BF, et al. 177Lu-DOTA(O), Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy. Int J Cancer 2001; 92(5): 628-33.
4. Leimer M, Kurtaran A, Smith-Jones P, et al. Response to treatment with yttrium 90-DOTA-lanreotide of a patient with metastatic gastrinoma. J Nucl Med 1998; 39: 2090-4.
5. Otte A, Jermann E, Behe M, et al. DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy. Eur J Nucl Med 1997; 24: 792-5.
6. Otte A, Herrmann R, Heppeler A, et al. Yttrium-90 DOTA-TOC: first clinical results. Eur J Nucl Med 1999; 26: 1439-47.
7. 3-octreotide. Eur J Nucl Med 2001; 28: 426-34.
8. 1-octreotide. In: Schlafke-Stelson A, Watson E, editors. Proceedings of Sixth International Radiopharmaceutical Dosimetry Symposium, Oak Ridge Associated Universities, Gatlinburg, TN, 1999. p. 127-36.
9. 1-octreotide in patients with neuroendocrine tumours. In: Schlafke-Stelson A, Watson E, editors. Proceedings of Sixth International Radiopharmaceutical Dosimetry Symposium, Oak Ridge Associated Universities, Gatlinburg, TN, 1999. p. 643-55.
10. Krenning EP, Bakker WH, Kooij PP, et al. Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide. J Nucl Med 1992; 33: 652-8.
11. 1-octreotide in patients, In: Schlafke-Stelson A, Watson E, editors. Proceedings of Sixth International Radiopharmaceutical Dosimetry Symposium, Oak Ridge Associated Universities, Gatlinburg, TN, 1999. p. 631-42.
12. 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake. J Nucl Med 1999; 40: 762-7.
13. 111In-DTPA0]octreotide in patients. Eur J Nucl Med 2001; 28: 1319-25.
14. Forssell-Aronsson E, Fjälling M, Nilsson O, Tisell LE, Wängberg B, Ahlman H. Indium-111 activity concentration in tissue samples after intravenous injection of indium-111-DTPA-D-Phe-1-octreotide. J Nucl Med 1995; 36: 7-12.
15. 111In-DTPA-D-Phe1-octreotide binding and somatostatin receptor subtypes in thyroid tumors. J Nucl Med 2000; 41: 636-42.
16. Kubota A, Yamada Y, Kagimoto S, et al. Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors. J Clin Invest 1994; 93: 1321-5.
17. Nilsson O, Kölby L, Wängberg B, et al. Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours. Br J Cancer 1998; 77: 632-7.
18. Scherubl H, Bader M, Fett U, et al. Somatostatin-receptor imaging of neuroendocrine gastroenteropancreatic tumors. Gastroenterology 1993; 105: 1705-9.
19. Tisell LE, Ahlman H, Wängberg B, et al. Expression of somatostatin receptors in oncocytic (Hurthle cell) neoplasia of the thyroid, Br J Cancer 111; 79: 1579-82.
20. 111In- octreotide binding in neuroendocrine tumours in relation to expression of somatostatin receptor subtype 2 studied by ribonuclease protection assay. Br J Surgery 2003; 90: 549-54.
21. Skånberg J, Ahlman H, Benjegård SA, et al. Indium-111-octreotide scintigraphy, intraoperative gamma detector localization and somatostatin receptor expression in primary human breast cancer. Breast Cancer Res Treat 2002; 74: 101-11.
22. Ahlman H, Wängberg B, Jansson S, et al. Interventional treatment of gastrointestinal neuroendocrine tumors. Digestion 2000; 62: 59-68.
23. Denzler B, Reubi JC. Expression of somatostatin receptors in peritumoural veins of human tumors. Cancer (1999); 85: 188-98.
24. Reubi JC, Laissue JA, Waser B, Steffen DL, Hipkin RW, Schonbrunn A. Immunohistochemical detection of somatostatin sst2a receptors in the lymphatic, smooth muscular, and peripheral nervous systems of the human gastrointestinal tract: facts and artifacts. J Clin Endocrinol Metab 1999; 84: 2942-50.
25. Stabin MG. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 1996; 37: 538-46.
26. 111In-DTPA-D-Phe-octreotide in man assessed by whole body scintigraphy. Acta Radiol 1994; 35: 7-53.
27. Stabin MG, Kooij PP, Bakker WH, et al. Radiation dosimetry for indium-111-pentetreotide. J Nucl Med 1997; 38: 1919-22.
28. Cremonesi M, Ferrari M, Chinol M, et al. Dosimetry in radionuclide therapies with 90Y-conjugates: the IEO experience. Q J Nucl Med 2000; 44: 325-32.
29. Virgolini I, Szilvasi I, Kurtaran A, et al. Indium-111-DOTA-lanreotide: biodistribution, safety and radiation absorbed dose in tumor patients. J Nucl Med 1998; 39: 1928-36.
30. Jamar F, Barone R, Mathieu I, et al. 86Y-DOTA0-D-Phe1-Tyr3-octreotide (SMT487) - a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. Eur J Nucl Med Mol Imaging 2003; 30: 510-8.